These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE. Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901 [Abstract] [Full Text] [Related]
5. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Takei M, Fukuda H, Kishii R, Hosaka M. Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337 [Abstract] [Full Text] [Related]
9. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Jones ME, Critchley IA, Karlowsky JA, Blosser-Middleton RS, Schmitz FJ, Thornsberry C, Sahm DF. Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071 [Abstract] [Full Text] [Related]
10. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059 [Abstract] [Full Text] [Related]
11. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Alkorta M, Giménez MJ, Vicente D, Aguilar L, Pérez-Trallero E. Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487 [Abstract] [Full Text] [Related]
12. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B. Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024 [Abstract] [Full Text] [Related]
13. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus. Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ. Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409 [Abstract] [Full Text] [Related]
14. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Noguchi N, Okihara T, Namiki Y, Kumaki Y, Yamanaka Y, Koyama M, Wakasugi K, Sasatsu M. Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290 [Abstract] [Full Text] [Related]
15. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. Turner AK, Nair S, Wain J. J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934 [Abstract] [Full Text] [Related]
18. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Shultz TR, Tapsall JW, White PA. Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352 [Abstract] [Full Text] [Related]
19. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro. Ruiz J, Sierra JM, De Anta MT, Vila J. Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932 [Abstract] [Full Text] [Related]
20. Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin. Messina C, Cafiso V, Campanile F, Santagati M, Stefani S. New Microbiol; 2001 Oct; 24(4):347-53. PubMed ID: 11718372 [Abstract] [Full Text] [Related] Page: [Next] [New Search]